# AWARD NUMBER: W81XWH-18-1-0317 PC170484

TITLE: Vitamin D Deficiency Leads to Increased Intraprostatic Hormones in African American Men

PRINCIPAL INVESTIGATOR: Larisa Nonn

CONTRACTING ORGANIZATION: University of Illinois at Chicago College of Medicine, Department of Pathology, 840 S. Wood St Chicago, IL 60612

REPORT DATE: AUGUST 2021

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| n                              |                             |  | Form Approved  |                            |  |
|--------------------------------|-----------------------------|--|--|----------------------------|--|
|                                | EPORT DOC                   |  | OMB No. 0704-0188  |                            |  |
|                                |                             |  | ching existing data sources, gathering and maintaining the<br>ollection of information, including suggestions for reducing |                            |  |
| this burden to Department of D | efense, Washington Headquar | ters Services, Directorate for Info                            | ormation Operations and Reports  | (0704-0188), 1215 Jeff     | erson Davis Highway, Suite 1204, Arlington, VA 22202-            |
|                                |                             | y other provision of law, no perso<br>JR FORM TO THE ABOVE ADD |  | for failing to comply with | h a collection of information if it does not display a currently |
| 1. REPORT DATE                 |                             | 2. REPORT TYPE   |  | 3. [                       | DATES COVERED  |
| AUGUST 2021                    |                             | Annual   |  |                            | 5JUL2020 - 14JUL2021   |
| 4. TITLE AND SUBTIT            |                             |  |  |                            | CONTRACT NUMBER  |
|                                |                             |  |  |                            | 1XWH-18-1-0317   |
|                                |                             |  |  |                            | GRANT NUMBER   |
|                                |                             | 1-   |  |                            | 170484   |
|                                |                             | to Increased I   | ntraprostatic  | _                          |  |
| Hormones in Af                 | rican America               | n Men  |  | 5C.                        | PROGRAM ELEMENT NUMBER   |
|                                |                             |  |  |                            |  |
| 6. AUTHOR(S)                   |                             |  |  | 5d.                        | PROJECT NUMBER   |
| Larisa Nonn                    |                             |  |  |                            |  |
|                                |                             |  |  | 5e.                        | TASK NUMBER  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  | 5f                         |  |
|                                |                             |  |  | 51.                        |  |
| E-Mail: Inonn@uic              |                             |  |  |                            | PERFORMING ORGANIZATION REPORT                                   |
| 7. PERFORMING ORG              | ANIZATION NAME(S)           | AND ADDRESS(ES)  |  |                            |  |
|                                |                             |  |  | r                          | NUMBER   |
| University of                  |                             |  |  |                            |  |
| Chicago Colle                  |                             |  |  |                            |  |
| Department of                  | Pathology 84                | 0  |  |                            |  |
| S. Wood St Ch                  | icago, IL 606               | 12   |  |                            |  |
|                                | 5                           |  |  |                            |  |
| 9 SPONSORING / MO              | NITORING AGENCY             | NAME(S) AND ADDRES   | S(ES)  | 10                         | SPONSOR/MONITOR'S ACRONYM(S)                                     |
|                                |                             |  | 0(20)  | 10.                        |  |
| LLS Army Modical               | Beesersh and Mc             | torial Command   |  |                            |  |
| U.S. Army Medical              |                             |  |  |                            |  |
| Fort Detrick, Maryl            | and 21702-5012              |  |  | 11.                        | SPONSOR/MONITOR'S REPORT   |
|                                |                             |  |  |                            | NUMBER(S)  |
|                                |                             |  |  |                            |  |
| 12. DISTRIBUTION / A           | VAILABILITY STATE           | MENT   |  |                            |  |
|                                |                             |  |  |                            |  |
| Approved for Publi             | c Release: Distrib          | ution Unlimited  |  |                            |  |
|                                | ,                           |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
| 13. SUPPLEMENTAR               | NOTES                       |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
| 14. ABSTRACT                   |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
| Our most signi                 | ficant findin               | q for Y2 of thi  | s project is t   | he profound                | l defect in prostate   |
|                                |                             |  |  |                            | apports its role in hormone                                      |
|                                |                             |  |  |                            | ly expressed by African  |
| _                              |                             |  |  |                            | ound that it is higer in AA                                      |
|                                |                             |  |  |                            |  |
| _                              |                             |  | _  |                            | by estrogen and androgen   |
| in patient-der                 | ived stromal                | cells, valıdatı  | ng the microar   | ray data.                  |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
|                                |                             |  |  |                            |  |
| 15. SUBJECT TERMS              |                             | _  |  |                            |  |
| prostate cance                 | er, vitamin D,              | androgen, test   | osterone, mega   | lin, Lrp2                  |  |
|                                |                             |  |  |                            |  |
| 16. SECURITY CLASS             | IFICATION OF:               |  | 17. LIMITATION   | 18. NUMBER                 | 19a. NAME OF RESPONSIBLE PERSON                                  |
|                                |                             |  | OF ABSTRACT  | OF PAGES                   | USAMRMC  |
| a. REPORT                      | b. ABSTRACT                 | c. THIS PAGE   | -  |                            | •  |
| a. REFURI                      | J. ADJIKAUI                 | C. THIS PAGE   |  |                            | <b>19b. TELEPHONE NUMBER</b> (include area code)                 |
| Line also in 16 mil            | line and the second         | Line also in 1990 and  | Unclassified   | 14                         |  |
| Unclassified                   | Unclassified                | Unclassified   |  |                            | Standard Form 298 (Rev. 8-98)                                    |
|                                |                             |  |  |                            |  |

# **Table of Contents**

# Page

| 1. | Introduction                                     | .2    |
|----|--|-------|
| 2. | Keywords   | .2    |
| 3. | Accomplishments                                  | 3-8   |
| 4. | Impact   | .9    |
| 5. | Changes/Problems                                 | .10   |
| 6. | Products   | .11   |
| 7. | Participants & other collaborating organizations | 11-12 |
| 8. | Special reporting requirements                   | 12    |

# **1. INTRODUCTION**

This proposal is built around our hypothesis that intra-prostatic androgens and estrogen may be the link between two undisputable disparities in African American (AA) men; vitamin D deficiency and prostate cancer (PCa). We propose that the molecular response of prostate tissues to low vitamin D status leads to increased intracellular import of not only vitamin D, but also androgens and estrogens. In other words, intra-prostatic levels of estrogens and androgens may be higher in AA men because of a molecular "door" that was opened for vitamin D. This study may also shed light on inconsistent findings regarding circulating levels of hormones and PCa risk. Hormones, including vitamin D, androgens and estrogen, are bound to serum globulins with only 1-3% existing as free hormones in the circulation. The "Free Hormone Hypothesis" is commonly accepted and assumes that only unbound free hormones are accessible to tissues via diffusion, thus tissue hormone levels mirror circulating levels in the blood. Our recent findings in AA men challenge the Free Hormone Hypothesis as we have shown that prostate tissues express functional megalin protein, a membrane endocytic receptor, to internalize globulin-bound hormones. Megalin function is well-described in the kidney, but there is a paucity of studies on prostatic megalin. The Free Hormone Hypothesis excludes the presence of extra-renal megalin entirely. Both vitamin D binding protein (DBP) and sex hormone binding globulin (SHBG), which binds androgens and estrogens, bind to megalin for endocytosis. We observed that in AA men only, the expression of prostatic megalin increased with vitamin D deficiency and increased with the percentage of West African Ancestry.

We propose that long term vitamin D deficiency in AA men leads to a compensatory increase in megalin to maintain tissue levels when the serum is deficient. In turn, high megalin would also import more androgens and estrogens, thus driving hormonal carcinogenesis.

Hypothesis: Low vitamin D status in African American men drives increased androgen and estrogen import into the prostate via the membrane endocytic receptor megalin. The objective is to both determine clinical significance and to delve into the mechanisms that regulate of hormone import. T The effect of vitamin D deficiency on the serum and intra-prostatic distribution of androgens/estrogens will be examined in Aim 1. The results of Aim 1 will define the relationships between the hormones through correlative data. Whereas the experiments in Aim 2 will demonstrate that megalin as the mechanism of endocytic import for hormones using an *in vitro* model. Lastly, the third Aim will examine if pathways that are active in patient tissues are regulated by intra-prostatic hormone levels. Importantly, all of these experiments utilize patient specimens and patient-derived cells from benign areas of the prostate, which is critical to assess activities of vitamin D in regards to prostate cancer risk.

#### 2. KEYWORDS: prostate cancer, vitamin D, androgen, testosterone, megalin, Lrp2

#### **3. ACCOMPLISHMENTS:**

What were the major goals of the project? What was accomplished under these goals?

| <b>SPECIFIC AIM 1:</b> To determine relationship between intraprostatic concentrations of androgens and estrogens with vitamin D status in African American men. | <b>Timeline</b><br>(months) | UIC<br>(Nonn)<br>(Prins)<br>(Chen)<br>(Baumann) | <b>COH</b><br>(Kittles) | <b>UPenn</b><br>(Penning) |
|--|-----------------------------|---|-------------------------|---------------------------|
| Major Task 1: Measure and quantify hormones in patient<br>serum and frozen prostate tissue in Cohort 1   | 1-36                        |   |                         |                           |
| Subtask 1: Procure de-identified tissue for LC-MS/MS optimization and send to Penning Lab  | 1-2                         | Completed                                       |                         |                           |
| Subtask 2: Optimize LC-MS/MS method  | 2-6                         |   |                         | Completed                 |
| Major Task 2: Measure and quantify hormones in patient<br>serum and frozen prostate tissue in Cohort 2   |                             |   |                         |                           |

| Subtask 1: Procure all patient tissues and sera for Cohort 2<br>from UIC Biorepository and PCBN and send to Penning<br>Lab           | 2-9   | N=209<br>samples<br>collected |                | N=63<br>sample<br>awaiting<br>analysis |
|--|-------|-------------------------------|----------------|--|
| Subtask 2: Perform LC-MS/MS on Cohort 2 patient samples  | 12-24 |                               |                | In<br>progress                         |
| Major Task 3: Determine West African Ancestry estimates patients in Cohort 2   |       |                               |                |  |
| Subtask 1: Procure all buffy coat for Cohort 2 from UIC<br>Biorepository and PCBN and send to Kittles Lab                            | 2-9   | Completed                     |                |  |
| <b>Subtask 2:</b> DNA isolation and SNP ancestry analysis of Cohort 2  | 9-24  | DNA<br>isolated               | Completed      |  |
| <b>Subtask 3:</b> SNP analysis of vitamin D-related polymorphisms in Cohort 2  | 9-24  |                               | Not<br>started |  |
| Major Task 4: Statistical analysis of the data   | 9-36  |                               |                |  |
| Subtask 1: Collect and organize data from Cohort 1and<br>meet with Dr. Yi-fan Cheng in UIC Analysis core                             | 9-12  | Completed                     |                |  |
| Subtask 2: Analysis of Cohort 1 by Dr. Yi-Fan Chen   | 12-18 | Completed                     |                |  |
| Subtask 3: Collect and organize Cohort 2 data from<br>Penning and Kittles labs and meet with Dr. Yi-fan Chen in<br>UIC Analysis core | 12-24 | In<br>progress                |                |  |
| Subtask 4: Analysis of Cohort 2 by Dr. Yi-Fan Chen   | 12-36 | In<br>progress                |                |  |

# Summary of Aim 1 Accomplishments:

**Y1:** Significant progress has been made on this aim with optimization of the method for testosterone metabolites in prostate tissues being completed (**Figure 1**). Optimization of detection of estrogen metabolites in prostate tissue is ongoing. Patient samples of tissue, sera and buffy coat have been collated for 48 patients and prepared for shipment to UPENN and COH.

|          |             |              | Т               | DHEA            | DHT             | Epi-AD          | AD              |
|----------|-------------|--------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|          |             | mg<br>tissue | pg/mg<br>tissue | pg/mg<br>tissue | pg/mg<br>tissue | fg/mg<br>tissue | fg/mg<br>tissue |
| S-13T-01 | TURP tissue | 45.6         | 1.19            | 15.2            | 0.03            | 12.18           | 5.06            |
| S-13T-02 | TURP tissue | 50.9         | 1.09            | 11.5            | 0.02            | 3.00            | 11.90           |
| S-14T-01 | TURP tissue | 52.3         | 0.15            | 6.7             | 1.29            | 477.16          | 224.82          |
| S-14T-02 | TURP tissue | 54.1         | 0.13            | 7.1             | 1.08            | 423.37          | 241.53          |
| S-15T-01 | TURP tissue | 44.3         | 0.14            | 5.9             | 0.55            | 351.80          | 90.33           |
| S-15T-02 | TURP tissue | 48.5         | 0.11            | 11.1            | 0.91            | 382.40          | 165.61          |
| S-16-01  | RP tissue   | 58.1         | 0.01            | 0.7             | 0.08            | 403.10          | 86.01           |
| S-16-02  | RP tissue   | 55.2         | 0.09            | 0.2             | 0.06            | 175.49          | 63.92           |
| S-17-01  | RP tissue   | 42.6         | 0.03            | 4.5             | 0.06            | 269.27          | 240.81          |
| S-17-02  | RP tissue   | 57.6         | 0.02            | 4.4             | 0.14            | 297.28          | 419.21          |

**Figure 1.** Optimization of testosterone metabolite detection in human prostate tissues by LC-MS/MS (Penning Lab)

**Y2:** All samples have been collected for this Aim. This includes presurgical serum, DNDA and frozen tissue from 200 PCa patients. In the end, the cohort is comprised of 125 UIC patients and 75 from PCBN. Samples have been labeled and the first batch of 63 was sent to Penning in September of 2019.

There have been three unforeseen delays with this aim:

- MS/MS at U PENN as initially delayed due to personnel shortage
- SNP analysis at COP was delayed due to a lab shutdown and move
- Both are now delayed due to the covid-19 pandemic. Both institution are operating with single day shifts per week for each employee.

However, since all specimens are collected and methods optimized, we anticipate rapid progress as soon as the labs are functioning at capacity.

**Y3:** The pandemic significantly delayed analyses due to delays in sample acquisition and closed core facilities at both UPenn and COH. As of August 2021, all samples have been sent to UPenn, COH and Heartland labs. We have completed analyses of serum androgens, serum vitamin D and ancestry. In both cohorts we observed reduced serum T and serum D in AA patients (by ancestry) (**Figure 2**). Estrogens were examined but undetectable in the majority of sera. Tissue hormone levels are in progress.



| <b>SPECIFIC AIM 2:</b> To delineate the role of megalin-<br>mediated endocytic transport in determining<br>intracellular levels of androgens, estrogens and vitamin<br>D in human primary prostatic cells from African-<br>American men | <b>Timeline</b> (months) | UIC<br>(Nonn)<br>(Prins)<br>(Chen)<br>(Baumann) | <b>UPenn</b><br>(Penning) |
|---|--------------------------|---|---------------------------|
| Major Task 1: To determine if internalization of 25D, T and E2 in prostate epithelium is dependent on megalin   | 1-18                     |   |                           |
| <b>Subtask 1:</b> Obtain deuterated hormones (vitamin D, estrogens and androgens) and make sufficient volume of shRNA-LRP2 lentivirus   | 1-3                      | Completed                                       |                           |
| Subtask 2: Conduct organoid experiments   | 3-18                     | In<br>progress                                  | In<br>progress            |
| <b>Subtask 3:</b> Ongoing analysis of findings as we replicate in N=10 AA PrE cells N=10 EA PrE cells   | 3-18                     | Not<br>started                                  |                           |
| Major Task 2: To examine the effects of vitamin D   |                          |   |                           |
| deficiency on megalin-mediated hormone<br>endocytosis in prostate epithelium  |                          |   |                           |
| Subtask 1: Conduct organoid experiments   | 3-18                     | In<br>progress                                  | In<br>progress            |
| Subtask 2: Ongoing analysis of findings as we<br>replicate in N=10 AA PrE cells and N=10 EA PrE<br>cells  | 3-18                     | Not<br>started                                  |                           |

| Major Task 3: To determine if internalization of 25D, T and E2 in prostate epithelium is dependent on megalin in vivo | 18-36 |           |           |
|---|-------|-----------|-----------|
| <b>Subtask 1:</b> Induce megalin knockout in ER-Prob-<br>cre, lrp2 <sup>fl/fl</sup> mice                              | 18-24 | Completed |           |
| Subtask 2: Prostate harvest and send to Penning<br>Lab for LC-MS/MS measurements of hormones                          | 24-30 | Completed | Completed |
| <b>Subtask 2:</b> Histological examination with Pathologist   | 24-36 | Completed |           |

## Summary of Aim 2 Accomplishments:

**Y1:** Optimization of the method to detect estrogens and androgens in the in vitro cells have been optimized (**Figure 3**) (Major Task 1). ShLrp2-lentivirus has been obtained for the organoids experiments (Major Task 1).

The 2 colonies of ER-Prob-cre and Lrp2-floxed mice are breeding well. Initial crosses began in June (Major Task 3).

|      |             |          | EpiT | Testosterone | DHEA | Androsterone | DHT  | Epi-         | 5-androstenediol | 3a-            | 3b-            |
|------|-------------|----------|------|--------------|------|--------------|------|--------------|------------------|----------------|----------------|
|      |             |          |      |              |      |              |      | androsterone |                  | androstenediol | androstenediol |
| S-01 | cell media  | EtOH     | NF   | 1173         | NF   | 1578         | NF   | NF           | NF               | 1828           | 1671           |
| S-02 | cell media  | 10 nM T  | NF   | 142907       | NF   | 658242       | NF   | 21569        | NF               | 6187           | NF             |
| S-03 | cell media  | 50 nM T  | NF   | 651697       | 2300 | 3177334      | NF   | 116135       | NF               | 21424          | 381            |
| S-04 | cell media  | 10 nM E2 | NF   | 14028        | NF   | 76010        | NF   | 2165         | NF               | 135            | 118            |
| S-05 | cell media  | 50 nM E2 | NF   | 2624         | NF   | 18937        | NF   | NF           | NF               | 424            | 180            |
|      |             |          |      |              |      |              |      |              |                  |                |                |
| S-06 | cell pellet | EtOH     | NF   | 2672         | NF   | 327          | NF   | NF           | NF               | 222            | NF             |
| S-07 | cell pellet | EtOH     | NF   | 82           | NF   | 83           | 11   | NF           | NF               | 11             | NF             |
| S-08 | cell pellet | EtOH     | NF   | 266333       | NF   | 117          | 54   | NF           | NF               | 264            | NF             |
| S-09 | cell pellet | 10 nM T  | NF   | 140355       | NF   | 31368        | NF   | NF           | 580              | 1377           | 829            |
| S-10 | cell pellet | 50 nM T  | NF   | 224413       | NF   | 143210       | NF   | NF           | 3200             | 6959           | 269            |
|      | cell pellet | 10 nM E2 | NF   | 1761         | NF   | 82           | 34   | NF           | NF               | NF             | NF             |
| S-11 |             |          |      |              |      | 128          | 1284 | NF           | NF               | NF             | NF             |

**Figure 3.** Optimization of testosterone and estrogen metabolite detection in patient derived cell cultures by LC-MS/MS (Penning Lab)

# Y2:

**Optimized vitamin D import assays:** In partnership with Heartland Assays, we optimized the dose and timing of 25D to quantify import into the organoids (data not shown). In Y3 we will complete the assays, along with the T and E2 optimized in Y1, in the organoids.

Knockout of Lrp2 in prostate organoids: We encountered difficulties with the shLrp2 lentivirus. Although we have good transduction, the knockdown of Lrp2 is minimal. We suspect that there are splice variants in the

prostate that do not respond to the nucleic acid sequences we have tried. Lrp2 is 80 exons, thus multiple splice variants are highly likely, but have yet to be reported. We are mapping the cDNA and designing new sequences. As all endpoints have been optimized, the experiments with the patientderived organoids will progress quickly once we have the correct shLrp2 sequences.

In the meantime, we have utilized our Lrp2KO mice for the organoid experiments. Organoids without Lrp2 have profound reduction in size, number and shape (**Figure 4**). These were cultured in standard organoid medium with SHBG-T used instead of DHT, to require Megalin for import. Ongoing experiments will complete these experiments in the presence of vitamin D deficiency.



**Knockout of Lrp2 in mouse prostate:** The crossed bitrans  $Lrp2^{fl/fl}$  /Pr-Mer-Cre-Mer mouse line has been established and is breeding well. We discovered unexpected side effects of tamoxifen treatment (to induce cre) on the male reproductive organs and had to modify our protocols and endpoints accordingly. These findings have been minimally reported in the literature, but we will include in our publication. Tamoxifen induced a complete seminal vesicle atrophy that takes 6 weeks to recover.



y Figure 5. Mouse prostates from 8 week old mice. Pups were treated with Tamoxifen days 10-15. Left prostate has Lrp2-KO and right is control without cre.

We switched to treating pups with tamoxifen days 10-15. The prostates were collected at 8 weeks and showed atrophy of the prostate only in the  $lrp2^{fl/fl}$ /cre+ mice compared to

 $lrp2^{fl/fl}$  alone (Figure 5). All mice were treated with tamoxifen to control for hormonal effects of induction.

## Y3:

**Hormone import assays:** There was no progress with this portion of the aim due to back up a UPenn for LC-MS/MS. They became very delayed with the pandemic and we chose to prioritize the patient samples (shown above)

**Knockout of Lrp2 in prostate organoids:** We determined that organoids from mouse prostate do not have the cre recombination that we see in the intact prostate. This is likely due to survival of progenitor cells in culture, which do not express AR or probasin, thus would have the cre activated. The organoids do differentiate to AR+ luminal cells, which should be able to activate cre with TAM addition, however TAM potently inhibits growth of the organoids.

**Knockout of Lrp2 in mouse prostate**: We have completed the in vivo mouse work with the conditional Lrp2 in mouse prostate. We determined that prostate MEGALIN regulates prostatic androgen levels in vivo using the conditional prostate-specific *Lrp2*-knockout mouse. (Systemic *Lrp2* knockout is perinatal lethal in mice.) Mice were treated TAM at postnatal day 10 or 5 w of age and showed recombination of Lrp2 only in *Lrp2*<sup>fl/fl</sup>/cre+

prostates and not control mice or tail DNA (Figure 6A-C). Androgen levels were measured by LC-MS/MS in the lab of Dr. Trevor Penning and showed significantly lower T in the  $Lrp2^{fl/fl}/cre+$  (Figure 6D). Moreover, in both control and  $Lrp2^{fl/fl}$ /cre+mice, there was no correlation between serum T levels and prostate T levels, indicating prostate levels are not dictated by passive diffusion (Figure 6E). However, testes T and serum T were tightly correlated, as expected. Prostate vitamin D levels were also lower in  $Lrp2^{fl/fl}$ /cre+ mice, but did not reach significance as multiple prostates had to be pooled to detect vitamin D (data not shown)



**Figure 6.** Loss of *Lrp2* in mouse prostate reduces prostatic androgens. A, mouse model for conditional knockout of Irp2 in prostate epithelium. **B**, recombination of Lrp2 exons 71-75 after tamoxifen in prostate DNA (P) and not tail DNA (T) only in bitransgenic mice. PCR for exons 76-77 as positive control. **C**, experimental timeline and **D**, prostate levels of T and DHT quantified by LC-MS/MS for *Lrp2*<sup>1//1</sup> (p10 n=5, 5w n=4) and *Lrp2*<sup>1//1</sup> cre+ (p10 n=6, 5w n=5). Graphs shows mean with Max-Min bars. **E**, Heatmap of Pearson correlation coefficients **®** for tissue and serum androgens for TAM p10 mice, p-value shown within each cell.

| <b>SPECIFIC AIM 3:</b> To identify cancer risk pathways that associate with intra-prostatic hormone concentrations in prostate epithelium and stroma from African American and European American men | <b>Timeline</b><br>(months) | UIC<br>(Nonn)<br>(Prins)<br>(Chen)<br>(Baumann) |
|--|-----------------------------|---|
| Major Task 1: Complete Affymetrix Arrays of LCM-<br>isolated prostate stroma and identify cancer-related<br>pathways that associate with hormone and megalin<br>status                               | 1-18                        |   |
| <b>Subtask 1:</b> Select patients and run the arrays (Baumann)   | 1-6                         | Complete  |
| <b>Subtask 2:</b> Data analysis and comparison to epithelial array data  | 6-12                        | Complete  |
| Subtask 3: Data analysis and comparison to Cohort<br>1 full patient data included T and E measurements<br>(Specific Aim 1)   | 6-18                        | Completed                                       |
| Major Task 2: 2B: To examine megalin-mediated effects on organoids   | 18-36                       |   |
| Subtask 1: Design PCR primers and pathway phenotypes   | 18-24                       | Completed                                       |
| Subtask 2: Conduct organoid experiments using<br>shRNA to knockdown LRP2   | 24-36                       | In<br>progress                                  |

**Summary of Aim 3 Accomplishments: Y1:** The microarray on the stroma was completed as well as analysis of the data (Major Task 1). The gene expression from the arrays was analyzed with the prostatic levels of vitamin D (25D) and DHT as well as the % of west African ancestry (Figure 7). Several leads were generated from the correlations between hormone levels and gene expression (Figure 8). Several of the genes were validated by PCR and expression in patient tissues, including HSD17B7 in stroma, required for biosynthesis of sex steroids (Figure 9A-B).





Y2: After further validation we have focused in on stromal HSD17B7 as a top differentially expressed gene that is correlated with both vitamin D and androgens in the prostate. This enzyme mediates conversion of estrone to estradiol (Figure 9a). We quantified the TMA that was stained in Y1 using HALO software and found HSD17B7 to be higher in the stroma of AA men compared to those of European descent (EA) (Figure 9b). Additionally, validation in patient-derived prostate stromal cells from AA and EA men showed regulation of HSD17B7 gene expression by both estrogen and androgen (Figure 9c).

**Y3:** There has been no further progress on this aim. Dr. Baumann moved on and has a position with Genentech. She is still helping to assemble the publication on this aim.



## • What opportunities for training and professional development has the project provided?

The project provides training for postdoctoral fellow, Dr. Bethany Baumann, who is in Dr. Nonn's lab.

#### **Training Activities:**

One-on-one work with Dr. Nonn to go over data and prepare reports Mentorship of Julian Pacheco, formerly an undergraduate in the lab and now a medical student, on the project

#### Methods learned:

Analysis of gene expression profiling data Pathway analysis (GSEA and Ingenuity) RT-qPCR R statistical programming Patient-derived prostate organoid culture

#### **Professional Development:**

Informatics training by UIC Bioinformatics core on analysis of gene expression
Attendance to the Society for Basic Urology Research Conference, Fall 2018 and 2019
Attendance to American Urological Association Conference, Spring 2019
Attendance to local Chicago AUA Conference, Fall 2019
University of Illinois at Chicago Bioinformatics Certificate
Responsible Conduct of Research seminars on Mentoring, Conflict of Interest and Detrimental Research Practices.
University of Illinois at Chicago Your Future in Science seminars on Negotiations, Data Management, and Social Media in Science
University of Illinois at Chicago Postdoctoral Association Workshops on Leadership and Developing Transferrable Skills

#### • How were the results disseminated to communities of interest?

Nothing to Report.

Multiple Poster sessions at local and national conferences:

- College of Medicine Research Day 2
- Society for Basic Urology Research Conference
- UIC Cancer Center Research Day
- Vitamin D Workshop (promoted oral presentation)

#### • What do you plan to do during the next reporting period to accomplish the goals?

We are in NCE and wrapping up the final endpoint analyses.

#### 4. IMPACT:

#### • What was the impact on the development of the principal discipline(s) of the project?

The disparity in vitamin D deficiency in AA men is indisputable, but the significance remains controversial given that AA men do not have altered bone health. Our characterization of prostatic MEGALIN suggests tissue levels of vitamin D and other hormones are actively regulated, not passively regulated. In contrast to other hormones, there is a paucity of information regarding regulation of intra-

tissue levels of hormones. Given the potential for MEGALIN to regulate this process AND that MEGALIN is regulated by vitamin D, our data provide crucial new insight on the regulation of vitamin D and may explain PCa disparities in AA men.

#### • What was the impact on other disciplines?

These findings may extend to other hormone responsive tissues, such as breast, in which there is also a disparity in triple negative disease in AA women.

#### What was the impact on technology transfer?

Nothing to report

• What was the impact on society beyond science and technology?

Nothing to report

#### 5. CHANGES/PROBLEMS:

• Changes in approach and reasons for change

Nothing to report.

• Actual or anticipated problems or delays and actions or plans to resolve them

Initial delays in MS/MS and SNP analysis are detailed in the aims above. The COVID-19 global pandemic brought all research to a halt and caused backup at the core facilities run by Dr. Penning and Kittles. All samples have been analyzed now, except for tissues. Thus final results will be ready within this NCE.

• Changes that had a significant impact on expenditures

The pandemic has reduced our supply expenditures for 2020

• Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to report.

• Significant changes in use or care of human subjects

Nothing to report.

• Significant changes in use or care of vertebrate animals.

Nothing to report.

• Significant changes in use of biohazards and/or select agents

Nothing to report.

• Publications, conference papers, and presentations Website(s) or other Internet site(s) Technologies or techniques Inventions, patent applications, and/or licenses Other Products

We plan to submit these findings to Nature Communications and are final preparation of the manuscript.

# 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

#### • What individuals have worked on the project?

| Name:                                     | Larisa Nonn  |
|---|--|
| Project Role:                             | PI   |
| Researcher Identifier (e.g.<br>ORCID ID): |  |
| Nearest person month worked:              | 1.8  |
| Contribution to Project:                  | Dr. Nonn oversaw all aspects of this proposal and coordinated samples transfer between the UIC and UPENN |
| Funding Support:                          | NA   |

| Name:                                     | Gail Prins  |
|---|---|
| Project Role:                             | Co-I (Qualified Collaborator)   |
| Researcher Identifier (e.g.<br>ORCID ID): |   |
| Nearest person month worked:              | 1.2   |
| Contribution to Project:                  | Dr. Prins provided expertise on hormone<br>metabolism and signaling. Participating in all<br>project meetings and looking over project data |
| Funding Support:                          | NA  |

| Name:                                     | Michael Schlicht,   |
|---|---|
| Project Role:                             | Research Specialist   |
| Researcher Identifier (e.g.<br>ORCID ID): | NA  |
| Nearest person month worked:              | 9   |
| Contribution to Project:                  | Mr. Schlicht oversees the mouse colonies and creates ll primary patient-derived cell cultures |
| Funding Support:                          | NA  |

| Name:                       | Bethany Baumann                     |
|-----------------------------|-------------------------------------|
| Project Role:               | Nested Young Investigator (postdoc) |
| Researcher Identifier (e.g. |                                     |
| ORCID ID):                  |                                     |

| Nearest person month worked: | 3.6  |
|------------------------------|--|
|                              | Dr. Baumann performed all gene expression analyses and validation experiments. |
| Funding Support:             | NA   |

• Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to report

#### • What other organizations were involved as partners?

**Organization Name:** University of Pennsylvania **Location of Organization:** USA **Partner's contribution to the project**:

**Collaboration**: this project is collaborative with Dr. Penning. His role and effort, as well as that of his postdoctoral fellow, were detailed in the original funded proposal.

| Name:                                     | Trevor Penning   |
|---|--|
| Project Role:                             | Co-I (UPENN)   |
| Researcher Identifier (e.g.<br>ORCID ID): |  |
| Nearest person month worked:              | 0.6 calendar months  |
| Contribution to Project:                  | Dr. Penning is oversaw the LC-MS/MS analysis of the prostate tissue and cells. |
| Funding Support:                          | NA   |

| Name:                                     | Clementina Messaros   |
|---|---|
| Project Role:                             | Postdoctoral fellow UPENN   |
| Researcher Identifier (e.g.<br>ORCID ID): |   |
| Nearest person month worked:              | 3 calendar months   |
| Contribution to Project:                  | Dr. Messsaros conducted the isolation and<br>quantitation of the hormones by LC-MS/MS<br>analysis in the prostate tissue, sera and cells. |
| Funding Support:                          | NA  |

#### 8. SPECIAL REPORTING REQUIREMENTS

**COLLABORATIVE AWARDS:** Gail Prins is the qualified collaborator on this project. Both Drs Nonn and Prins are at UIC and only one report was submitted.